Making a Profound Impact, Together
As an early pioneer of microbiome science, OpenBiome has changed the landscape of healthcare. Along with our clinical and research partners, we use microbiome-based approaches to find research solutions for pressing public health issues.
Advancing Medical Science Worldwide
Microbiome-based therapies are a new frontier of medicine that present a promising option for patients who have exhausted standard treatments.
Since 2012, OpenBiome has provided more than 70,000 investigational fecal microbiota transplantation (FMT) preparations for patients with antibiotic-resistant C. difficile.
We’ve also pushed the boundaries of science by supporting clinical trials including THRIVE — the first FMT-focused clinical trial in Africa and the first to evaluate microbiome manipulation in children with malnutrition.
Transforming Healthcare Through Investigational Fecal Microbiota Transplantation
Healthcare facilities and research institutions in the United States have partnered with OpenBiome to provide access to investigational FMT under an IND for patients and perform clinical trials.
Patients with recurrent C. difficile infections have received urgently needed investigational fecal microbiota transplantation (FMT) preparations from OpenBiome.
Clinical trials exploring the therapeutic potential of the microbiome have received guidance and investigational FMT preparations provided by OpenBiome.